Ken Griffin’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.9M | Sell |
474,750
-267,368
| -36% | -$11.8M | ﹤0.01% | 2167 |
|
|
2025
Q4 | $30.6M | Buy |
742,118
+427,562
| +136% | +$17.2M | ﹤0.01% | 1878 |
|
|
2025
Q3 | $12.2M | Buy |
314,556
+47,163
| +18% | +$1.53M | ﹤0.01% | 2965 |
|
|
2025
Q2 | $7.4M | Buy |
267,393
+206,746
| +341% | +$5.26M | ﹤0.01% | 3466 |
|
|
2025
Q1 | $1.35M | Sell |
60,647
-243,929
| -80% | -$5.02M | ﹤0.01% | 6295 |
|
|
2024
Q4 | $6.02M | Buy |
304,576
+106,163
| +54% | +$2.42M | ﹤0.01% | 3668 |
|
|
2024
Q3 | $4.96M | Buy |
198,413
+143,593
| +262% | +$3.5M | ﹤0.01% | 3960 |
|
|
2024
Q2 | $1.02M | Sell |
54,820
-50,470
| -48% | -$946K | ﹤0.01% | 6531 |
|
|
2024
Q1 | $2.08M | Sell |
105,290
-109,406
| -51% | -$2.14M | ﹤0.01% | 5443 |
|
|
2023
Q4 | $3.77M | Buy |
214,696
+132,658
| +162% | +$2.18M | ﹤0.01% | 4244 |
|
|
2023
Q3 | $1.43M | Sell |
82,038
-119,796
| -59% | -$2.02M | ﹤0.01% | 5871 |
|
|
2023
Q2 | $2.84M | Buy |
201,834
+73,022
| +57% | +$977K | ﹤0.01% | 4562 |
|
|
2023
Q1 | $1.39M | Sell |
128,812
-88,288
| -41% | -$1.16M | ﹤0.01% | 6070 |
|
|
2022
Q4 | $3.25M | Buy |
217,100
+15,872
| +8% | +$231K | ﹤0.01% | 4624 |
|
|
2022
Q3 | $2.58M | Sell |
201,228
-159,181
| -44% | -$1.81M | ﹤0.01% | 5102 |
|
|
2022
Q2 | $3.49M | Buy |
360,409
+116,759
| +48% | +$1.09M | ﹤0.01% | 4477 |
|
|
2022
Q1 | $2.42M | Buy |
243,650
+175,865
| +259% | +$1.86M | ﹤0.01% | 5672 |
|
|
2021
Q4 | $798K | Buy |
67,785
+42,150
| +164% | +$518K | ﹤0.01% | 8492 |
|
|
2021
Q3 | $292K | Sell |
25,635
-95,849
| -79% | -$1.25M | ﹤0.01% | 11110 |
|
|
2021
Q2 | $1.69M | Sell |
121,484
-900,239
| -88% | -$13.7M | ﹤0.01% | 7005 |
|
|
2021
Q1 | $18.9M | Sell |
1,021,723
-43,011
| -4% | -$880K | ﹤0.01% | 2037 |
|
|
2020
Q4 | $18.8M | Sell |
1,064,734
-12,210
| -1% | -$214K | ﹤0.01% | 1869 |
|
|
2020
Q3 | $16.5M | Buy |
1,076,944
+369,737
| +52% | +$6.94M | ﹤0.01% | 1746 |
|
|
2020
Q2 | $18M | Buy |
707,207
+185,015
| +35% | +$3.86M | 0.01% | 1595 |
|
|
2020
Q1 | $8.08M | Buy |
522,192
+155,935
| +43% | +$2.44M | ﹤0.01% | 2101 |
|
|
2019
Q4 | $4.05M | Sell |
366,257
-2,333
| -0.6% | -$20.3K | ﹤0.01% | 3346 |
|
|
2019
Q3 | $3.14M | Sell |
368,590
-3,697
| -1% | -$40.9K | ﹤0.01% | 3777 |
|
|
2019
Q2 | $5.04M | Buy |
372,287
+246,442
| +196% | +$3.82M | ﹤0.01% | 3067 |
|
|
2019
Q1 | $2.27M | Buy |
125,845
+89,628
| +247% | +$1.73M | ﹤0.01% | 4253 |
|
|
2018
Q4 | $1.02M | Sell |
36,217
-17,376
| -32% | -$363K | ﹤0.01% | 5279 |
|
|
2018
Q3 | $1.37M | Sell |
53,593
-36,023
| -40% | -$700K | ﹤0.01% | 5021 |
|
|
2018
Q2 | $1.55M | Buy |
+89,616
| New | +$1.62M | ﹤0.01% | 4490 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
VPM
VCM
Ken Griffin's KNSA Position: Q1 2026 in Review
Ken Griffin reduced its Kiniksa Pharmaceuticals (KNSA) stake by 36% in Q1 2026, selling an estimated $11.8M and leaving 474,750 shares worth $22.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2167.
Ken Griffin first reported a position in KNSA in Q2 2018 and has held it in 32 quarters since. The position peaked at $30.6M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.
- Ken Griffin held 474,750 shares of Kiniksa Pharmaceuticals worth $22.9M as of Q1 2026.
- Ken Griffin sold 267,368 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $11.8M.
- Kiniksa Pharmaceuticals made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #2167 holding.
- Ken Griffin first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
- Ken Griffin's Kiniksa Pharmaceuticals position peaked at $30.6M in Q4 2025.
- 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.